Outcomes of anti-PD-L1 blockades plus etoposide and platinum (EP) as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) with brain metastasis (BM).

被引：0
|
作者：
Tian, Yaru
Ma, Ji
Zhu, Hui
Yu, Jinming
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Peoples Hosp Leling, Dept Oncol, Leling, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20607
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Impower133: Updated Overall Survival (OS) Analysis of First-Line (1L) Atezolizumab (ATEZO) plus Carboplatin plus Etoposide in Extensive-Stage SCLC (ES-SCLC)
    Reck, Martin
    Liu, Stephen V.
    Mansfield, Aaron S.
    Mok, Tony
    Scherpereel, Arnaud
    Reinmuth, Niels
    Garassino, Marina C.
    De Castro Carpeno, Javier
    Califano, Raffaele
    Nishio, Makoto
    Orlandi, Francisco
    Alatorre Alexander, Jorge Arturo
    Leal, Ticiana
    Cheng, Ying
    Lee, Jong-Seok
    Lam, Sivuonthanh
    Mccleland, Mark
    Deng, Yu
    Phan, See
    Horn, Leora
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 233 - 233
  • [42] A meta-analysis of trials of etoposide plus platinum agent versus irinotecan/topotecan plus platinum agent in first-line therapy of extensive stage small cell lung cancer (ES SCLC)
    Ellis, Peter Michael
    Durocher-Allen, Lisa
    Vella, Emily
    Sun, Alexander
    Ung, Yee
    Ramchandar, Kevin
    Darling, Gail Elizabeth
    Goffin, John R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)
    Reck, M.
    Liu, S. V.
    Mansfield, A. S.
    Mok, T. S. K.
    Scherpereel, A.
    Reinmuth, N.
    Garassino, M. C.
    De Castro Carpeno, J.
    Califano, R.
    Nishio, M.
    Orlandi, F.
    Alatorre Alexander, J. A.
    Leal, T. A.
    Cheng, Y.
    Lee, J-S.
    Lam, S.
    McCleland, M.
    Deng, Y.
    Phan, S.
    Horn, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 710 - +
  • [44] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 36-monthoverall survival from the Phase 3 CASPIAN study
    Paz-Ares, Luis
    Schulz, Christian
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 148 - 149
  • [45] Consolidative and salvage thoracic radiotherapy (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) with first-line chemoimmunotherapy: a retrospective study from a single cancer center
    Lan, Aihua
    Dong, Huiling
    Zheng, Zhiqin
    Chu, Xiao
    Zhu, Zhengfei
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2025, 55
  • [46] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
    Ozguroglu, M.
    Goldman, J. W.
    Reinmuth, N.
    Chen, Y.
    Dvorkin, M.
    Trukhin, D.
    Statsenko, G.
    Hotta, K.
    Ji, J. H.
    Hochmair, M. J.
    Voitko, O.
    Havel, L.
    Poltoratskiy, A.
    Losonczy, G.
    Verderame, F.
    Thomas, M.
    Zheng, Y.
    Lloyd, A.
    Jiang, H.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 66 - 66
  • [47] Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study.
    Ozgurogiu, Mustafa
    Goldman, Jonathan W.
    Chen, Yuanbin
    Garassino, Marina Chiara
    Medic, Nenad
    Mann, Helen
    Chugh, Priti
    Dalvi, Tapashi
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC)
    Chu, Q.
    Parikh, K.
    Paz-Ares, L.
    Navarro, A.
    Markman, B.
    Sarmiento, R.
    Kollia, G.
    He, C.
    Sanghavi, K.
    Chang, H.
    Fischer, B.
    Guha, U.
    Tannenbaum-Dvir, S.
    Wu, K.
    Liu, Y.
    Ready, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1170 - S1170
  • [49] Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as fi rst-line therapy for extensive-stage small-cell - cell lung cancer (ES-SCLC): a phase II trial
    Chen, Dawei
    Zou, Bing
    Li, Butuo
    Gao, Aiqin
    Huang, Wei
    Shao, Qian
    Meng, Xiangjiao
    Zhang, Pinliang
    Tang, Xiaoyong
    Hu, Xudong
    Zhang, Yan
    Guo, Jun
    Zhao, Changhong
    Yuan, Jiajia
    Li, Qian
    Zhu, Changbin
    Yu, Jinming
    Wang, Linlin
    ECLINICALMEDICINE, 2024, 75
  • [50] KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)
    Peled, N.
    Rodriguez-Abreu, D.
    Bordoni, R.
    Ellis, P. M.
    Hochmair, M.
    Mueller, V.
    Levchenko, E.
    Zhou, H.
    Zhao, B.
    Lara-Guerra, H.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1425 - S1425
12345